In 2020, Oregonians voted to legalize the use of psilocybin mushrooms in therapeutic settings. This came as fresh research showed promising results of psychedelic therapy for depression, PTSD and substance use disorder. Now a new kind of patient is seeking out this care. As reported in the New York Times, some people are seeking psychedelics, such as ketamine and psychedelic mushrooms, for palliative care. Andrew Jacobs is a health and science reporter for the Times. He joins us to share more.
